BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 20, 2014
View Archived Issues
Doxofylline receives FDA orphan drug status for bronchiectasis
Read More
ONC1-13B shows high efficacy in preclinical models of prostate cancer
Read More
ProTide technology applied to anticancer agents to overcome drug resistance
Read More
BioAtla grants BioMotiv worldwide rights to IL-22 antibody
Read More
Pivotal trial of LDE-225 in advanced basal cell carcinoma meets primary endpoint
Read More
CURx Pharmaceuticals enters into license agreement with Gilead Sciences
Read More
Phase III ramucirumab lung cancer trial meets primary endpoint of overall survival
Read More
Zealand Pharma prepares novel glucagon receptor agonists
Read More
Insmed provides interim update from extension study of Arikace in cystic fibrosis
Read More
Omeros doses first patient in second phase II trial of OMS-824
Read More
Oritavancin NDA accepted by FDA for filing
Read More
Researchers at Proximagen present new PAR-2 antagonists
Read More
Preclinical results presented for RTL-1000 as a therapeutic agent for stroke
Read More
Actavis to acquire Forest Laboratories
Read More
Cellceutix submits IND for Prurisol trial, begins enrollment in phase IIb trials of brilacidin
Read More
Onconova discloses results from phase III trial of intravenous rigosertib in higher risk MDS
Read More
Nerviano Medical Sciences discloses novel JAK inhibitors
Read More
Michael J. Fox Foundation awards grant to Ezose Sciences
Read More
New H+/K+-ATPase inhibitors designed for gastrointestinal and other disorders
Read More
Bayer begins phase III COAST trial of regorafenib
Read More
Korean group prepares novel MAbs for cancer
Read More
PAK-01 enhances reperfusion and neuroprotection with no hemorrhagic transformation in vivo
Read More
Dilafor and Lee's Pharmaceutical sign license agreement for tafoxiparin in China
Read More